Načítá se...
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
BACKGROUND/AIMS: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical prac...
Uloženo v:
| Vydáno v: | Clin Mol Hepatol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Korean Association for the Study of the Liver
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7820195/ https://ncbi.nlm.nih.gov/pubmed/33317251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2020.0180 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|